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’INTRODUCTION
A number of bioactive compounds of current interest are
discovered by phenotypic screening,
1,2 most of which are func-
tionalinnaturethroughanalyzingthecompound-inducedeﬀects
incells,tissues,andmodelorganisms.Theseassays,however,can
hardly provide immediate target information for tested com-
pounds, imposing grand challenges on follow-up target identiﬁ-
cationfor drug discovery.
3 5 The recentﬁndingsthatmanydrugs
act on multiple physiological targets to exert therapeutic eﬀects
and/orsideeﬀectshaveattractedintensiveinterestinexploringthe
promiscuity and polypharmacology of drugs,
6,7 in which identify-
ing compound-target associations is a premise.
Experimentally, two major techniques are used for target
identiﬁcation.
3Directtechniques,suchasaﬃnitychromatography
8,9
andproteinmicroarray,
10detectthebindingofacompoundtoits
target.Theirapplicationsareoftenhamperedbytheneedtolabel
a compound without aﬀecting its functionality. Indirect tech-
niques infer targets from the compound-induced cellular or physio-
logical patterns through genomics,
11,12 proteomics,
13 metabolite
proﬁling,
14 and other technologies. However, genome-wide or
proteome-wide data could be very diﬃcult and expensive to
obtain.
Moreover, wet-lab experiments for target identiﬁcation are
often slow, whereas computational approaches can be eﬃcient
complements.
15 For example, molecular modeling studies have
been reported for target prediction by virtually docking a
compound of interest to a list of potential targets with known
three-dimensional (3D) structures.
16,17 The primary limitation
of this method is the need for high-resolution 3D structures of
targets as well as accurate docking/scoring algorithms.
18,19
Statistical models also have been built for target prediction
employingvariousmachinelearningmethodsincludingBayesian
analysis
20,21 and Support Vector Machines.
22 The common
drawbacksofthesemodelsarethattherealpredictabilitybeyond
training space cannot always be guaranteed. In addition, the
similarity principle,
23,24 despite its exceptions,
25 has been the
basis for target identiﬁcation using similarity metrics such as
ligand chemical similarity
5,7,26 and drug side eﬀects similarity.
4
On the other hand, with the rapid growth of public biological
databases, such as the Protein Data Bank
27 (PDB), PubChem,
28
ChEMBL (http://www.ebi.ac.uk/chembl), DrugBank,
29,30 and
Therapeutic Targets Database
31,32 (TTD), abundant bioactivity
data of small molecules and their targets are now available to the
entire research community. It is thus getting critical to develop
in silico methods to identify compound-target associations and
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ABSTRACT: Molecular target identiﬁcation is of central im-
portance to drug discovery. Here, we developed a computa-
tional approach, named bioactivity proﬁle similarity search
(BASS), for associating targets to small molecules by using
theknowntargetannotationsofrelatedcompoundsfrompublic
databases. To evaluate BASS, a bioactivity proﬁle database was
constructedusing4296compoundsthatwerecommonlytested
in the US National Cancer Institute 60 human tumor cell line
anticancerdrugscreen(NCI-60).Eachcompoundwasusedasa
query to search against the entire bioactivity proﬁle database,
andreferencecompoundswithsimilarbioactivityproﬁlesabove
a threshold of 0.75 were considered as neighbor compounds of
the query. Potential targets were subsequently linked to the
identiﬁed neighbor compounds by using the known targets of
the query compound. About 45% of the predicted compound-
targetassociationsweresuccessfullyveriﬁedretrospectively,suggestingthepossibleapplicationofBASSinidentifyingthetargetsof
uncharacterized compounds and thus providing insight into the study of promiscuity and polypharmacology. Furthermore, BASS
identiﬁed a signiﬁcant fraction of structurally diverse compounds with similar bioactivities, indicating its feasibility of “scaﬀold
hopping” in searching novel molecules against the target of interest.2441 dx.doi.org/10.1021/ci200192v |J. Chem. Inf. Model. 2011, 51, 2440–2448
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infer targets for drugs and bioactive compounds by aggregating
and integrating valuable target information from multiple
resources.
End points of bioactivity data obtained from a panel of assays
(i.e., bioactivity proﬁle) may provide distinct insight to the
biologicalfunctionof compoundsand theirtargets.For example,
the COMPARE algorithm,
33 by the Developmental Therapeu-
tics Program (DTP) of the US National Cancer Institute (NCI),
could be used to suggest possible mechanism of action for a
respective compound from related compounds or identify novel
compoundsthatactbyasimilarmechanismofinterest.
34 36This
tool compares the bioactivity patterns derived from the anti-
cancer drug screening data across 60 human tumor cell lines
(commonly known as the NCI-60 data set). By incorporating
additional gene expression data, target information may be
inferred.
34
The NCI-60 data set was also used in our previous work,
37
where we observed in a few model systems that the target
networks of small molecules were well-correlated with their
bioactivity proﬁles. Here, given the rapid growth in available
compound-target annotations in several public databases, we
further investigated whether such correlations could be utilized
tobeneﬁttheidentiﬁcationofnewtargetsfordrugsandbioactive
compounds on a larger scale. To this end, we ﬁrst constructed a
database of bioactivity proﬁles for 4296 compounds tested in the
NCI-60 data set. Second, we used each compound as a query to
search against the entire bioactivity proﬁle database to identify
neighbor compounds with similar bioactivity proﬁles. Third, we
collectedtargetinformationfromfourpublicdatabases(DrugBank,
TTD, ChEMBL and PubChem) for both query compounds and
their neighbor compounds to evaluate our approach for predict-
ingcompound-target associations. The underlying assumptionis
that compounds with similar bioactivity proﬁles may share
common targets. We were able to verify a remarkable portion
of our predictions retrospectively.
’METHODS
Construction of Bioactivity Profile Database. The NCI-60
data set contains anticancer screening results for more than
40,000 compounds. It is publicly available in the PubChem
BioAssay database
38 as 73 bioassays with the name of “NCI
humantumorcelllinegrowthinhibitionassay”underthe“DTP/NCI”
data source. In this work, only the top 60 bioassays (referred
hereafter as NCI-60) with the largest number of tested com-
pounds were selected (Supporting Information, Table S1).
Relevant bioactivity data were downloaded at the PubChem
FTP site (ftp://ftp.ncbi.nlm.nih.gov/pubchem/Bioassay, ac-
cessed on December 9, 2010). A total of 5083 compounds were
foundcommonlytestedinallofthe60bioassays.Thebioactivity
profile of each compound was derived by extracting the
log(GI50) values obtained from the NCI-60 cell lines, where
GI50 is the concentration required for the 50% growth inhibition
of tumor cells. 631 compounds with missing log(GI50) value in
one or more of the NCI-60 cell lines were discarded. Additionally,
156 compounds were further discarded, because they exhibited
identical bioactivity in all NCI-60 cell lines, which made them
less informative and unsuitable for bioactivity profile similarity
calculation (see below). As a result, 4296 compounds were
collected and used for constructing the bioactivity profile data-
base. The original bioactivity profile data for these compounds
are available in Supporting Information, Table S2. Additional
data set characteristics are summarized in Supporting Informa-
tion, Figure S1 with respect to six physiochemical properties:
molecularweight,octanol waterpartitioncoefficient,
23number
of hydrogen bond donors, number of hydrogen bond acceptors,
number of rotatable bonds, and topological polar surface area.
BioActivity Profile Similarity Search (BASS). The BASS
approach consists of three major steps (Figure 1). For a given
querycompoundintheNCI-60dataset,wefirstsearchedagainst
the entire bioactivity profile database and calculated pairwise
bioactivity profile similarity for each reference compound in the
datasetandthequerycompound.Second,aneighborcompound
wasidentifiedifitsbioactivityprofilesimilarityisaboveaselected
threshold. Finally, the known target of the query compound is
predicted as the potential target of its neighbor compounds or
vice versa. A critical step of BASS is to identify the neighbor
compounds for a given query compound based on the similarity
of bioactivity profiles (Simbio), which is defined as Pearson cor-
relation coefficient (Rp)
Simbio ¼ Rp ¼
∑
N
i¼1
ðxi   ̅xÞðyi   ̅yÞ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
∑
N
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ðxi   ̅xÞ
2
s ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
∑
N
i¼1
ðyi   ̅yÞ
2
s ð1Þ
whereNequals60,andxiandyiarethelog(GI50)valuesofthei
th
NCI-60 cell line for compound Q and compound S, respectively.
In this work, S is considered as a neighbor compound of Q when
Simbio is above 0.75. This similarity threshold was chosen based
on a statistical test, which was carried out by randomly selecting
two compounds from the entire bioactivity profile database for
100,000 times and recording each time the bioactivity profile
similarity. A probability (p-value) was subsequently calculated
for obtaining a bioactivity profile similarity above a certain
threshold. For the similarity threshold of 0.75 (p-value = 2.28e-3),
we found a good balance between prediction accuracy and the
number of predictions.
Compilation of Target Information. Target annotations for
all the compounds in the bioactivity profile database were primarily
collected from four public databases: DrugBank,TTD,ChEMBL,
and PubChem. For DrugBank (http://www.drugbank.ca) and
TTD (http://bidd.nus.edu.sg/group/cjttd/TTD_HOME.asp),
Figure 1. Schematic overview of the bioactivity proﬁle similarity search
(BASS) strategy. Target prediction can be bidirectional, that is, the
known targets of a query compound can be predicted as the potential
targets of its neighbor compound, or vice versa.2442 dx.doi.org/10.1021/ci200192v |J. Chem. Inf. Model. 2011, 51, 2440–2448
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compound-target associations were downloaded from original
Web sites (both accessed on December 9, 2010). For ChEMBL,
the mirrored version of ChEMBL_08 in PubChem was used
(http://pubchem.ncbi.nlm.nih.gov, accessed on December 9,
2010),andweconsideredacompound-targetassociationwhena
respective compound exhibited an effective activity concentra-
tione1μMagainstitsdirectlyassignedtarget.ForPubChem,the
bioactivity outcome specifications from original bioassay deposi-
tors were adopted to establish compound-target associations.
Additionally, we also manually collected the target annotations
for a number of compounds from precedent literatures using the
‘LiteratureKeywordMiningTool’providedatPubChem.Froma
list of MeSH terms (http://www.ncbi.nlm.nih.gov/mesh) re-
turned by this tool, we looked into the most relevant ones to the
compound and/or target of interest and then followed the links
to full-text literature and extracted evidence therein whenever
possible. All protein targets were uniformlystored as UniProtKB
identifiers (http://www.uniprot.org, accessed on February 4,
2011). Other molecular targets, such as DNA and RNA, were
stored as target names. As a result, 237 compounds with known
target annotations in one or more of the above four databases
were identified (Table 1).
’RESULTS
Evaluation of BASS for Target Identification. Using the
above237compoundswithknowntargetannotationsasqueries,
BASSpredicted atotalof4693compound-targetassociations for
neighbor compounds, i.e., the known targets of a respective
query compound were considered as the potential targets of its
neighborcompounds. Inthis work, ifatleast onepotentialtarget
wasalsoannotatedinanyoftheabovefourdatabases,asuccessful
prediction of the compound-target association was counted. It
should be noted that only a part of such predictions could be
evaluated when both query compound and neighbor compound
had target annotationsavailable. 634 outof the4693compound-
target associations turned out to be verifiable. For a systematic
evaluation of the predicted associations, a stringent criterion was
first used by checking the identity of targets of the query
compound and its neighbor compound. As a result, a success
rate of 44.8% (284 successful predictions) was achieved, which
accounted for 103 out of the 237 query compounds. When the
identified targets were proteins and there was no exact match
among that of a respective compound and its neighbor com-
pound, a less stringent criterion of target identity was applied
if protein target sequences were significantly related. In this
work, two protein targets that showed an E-value <1e-12 in the
BLAST
39 protein protein sequence alignment were considered
as biologically related. Under these conditions, the performance
was further improved to 48.6% (308 predictions in total), which
accounted for 108 out of the 237 query compounds. The above
evaluation suggested that BASS, when combined with searching
targetinformationusingpublicdatabases,maybeusedtoidentify
targets for biological neighbor compounds with similar bioactivity
profiles to a query compound. Detailed results are described for
the following examples, with the complete results provided in
Supporting Information, Table S3.
MicrotubuleasaNewTarget.Microtubulesarecomposedof
R- and β-tubulin heterodimers. They are cytoskeletal elements
involved in many cellular processes, such as mitosis, cytokinesis,
and vesicular transport.
40 42 Small molecules that bind to tubulin
can interfere with microtubule dynamics, resulting in microtubule
stabilization or destabilization, which induces cell cycle arrest and
ultimatelyleadstoapoptosis.Outofthe15newmolecularentities
approved by FDA in 2010, two are targeting microtubule.
43
Considering its key roles in mitosis and cell division, microtubule
continues to be a very important chemotherapeutic target of
anticancer drugs.
44
According to DrugBank (primary accession number, PAN:
DB01229), Paclitaxel (PubChem Compound identiﬁer, CID:
36314) is an FDA-approved drug to treat various cancers, including
ovarian cancer and breast cancer. It promotes the assembly of
microtubules from tubulin dimers and stabilizes them by pre-
ventingdepolymerization.Inthiswork,usingPaclitaxelasaquery
for BASS retrieved seven neighbor compounds (Figure 2A). These
included ﬁve closely related analogues of Paclitaxel, showing
an average two-dimensional chemical similarity (Simchem)o f
0.924 as characterized by PubChem ﬁngerprint (ftp://ftp.ncbi.
nlm.nih.gov/pubchem/speciﬁcations/pubchem_ﬁngerprints.txt)
and Tanimoto score.
45 This is consistent with previous observa-
tionsthatstructurallysimilarcompoundmayexhibitcomparative
bioactivities.
46,47 However, due to limited target annotations
available to us at the time, we were not able to verify tubulin as a
target for these structural analogs.
On the other hand, tubulin was veriﬁed as a target for one
neighbor compound Vinblastine (CID: 241902; Simbio = 0.785;
p-value = 1.31e-3) which was structurally unrelated to Paclitaxel
(Simchem = 0.560, Figure 2A). Vinblastine is an approved anti-
cancerdrug(PAN:DB00570)whichisthoughttoplayakeyrole
inmitosisinhibitionatmetaphaseviaitsinteractionwithtubulin.
The crystal structure of Vinblastine-tubulin complex reveals
that Vinblastine binds at the interface between two tubulin
heterodimers,
40 in contrast to Paclitaxel which binds at the taxol
site of β-tubulin.
42 Furthermore, using Vinblastine as a query,
BASS identiﬁed a number of neighbor compounds that were
common to those of Paclitaxel. Interestingly, this second search
identiﬁed two additional neighbor compounds which were
previously reported as tubulin inhibitors (CID: 249332
48,49
and 347381;
50 Simbio = 0.753 and 0.756; p-value = 2.25e-3 and
2.12e-3; Simchem = 0.984 and 0.526, respectively). In addition,
BASS identiﬁed another non-Paclitaxel neighbor compound
NSC355256 (CID: 434718; Simbio = 0.789; p-value =1.14e-3;
Simchem=0.671)usingPaclitaxelasaquery(Figure2A).Dueto
limited target annotation available to us, we were unable to
verify tubulin as a target for this compound. However, we
noticedthatitsharedthechemicalscaﬀoldofanapproveddrug
Colchicine (PAN: DB01394; CID: 6167) with a signiﬁcant
structural similarity (Simchem = 0.878). As indicated by the
crystal structure of Colchicine-tubulin complex, Colchicine
binds to the β-tubulin subunit of microtubule at the interface
with R-tubulin.
41 This example indicated that BASS had the
potential to discover novel inhibitors and explore new starting
points for lead optimization, demonstrating the advantage of
BASS for identifying compounds with various chemical scaf-
folds, which may provide insight to ‘scaﬀold hopping’ against
the target of interest.
51,52
Table 1. Summary of the 237 Compounds with Target
Annotations in Relevant Public Databases
DrugBank TTD ChEMBL PubChem
no. of compounds 28 33 23 215
no. of target annotations 44 50 67 10462443 dx.doi.org/10.1021/ci200192v |J. Chem. Inf. Model. 2011, 51, 2440–2448
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Dihydrofolate Reductase As a New Target. In the above
example,wedemonstratedthatthetargets ofbiologicalneighbor
compounds could be inferred from the known targets of a drug
molecule. It would be more practical and interesting to investi-
gate, from a reverse perspective, whether BASS could be used to
suggest new targets for a drug molecule by gathering known
target information from its neighbor compounds (Figure 1).
Dihydrofolate reductase (DHFR) converts dihydrofolate into
tetrahydrofolate.Thelatterisamethylgroupshuttlerequiredfor
the de novo biosynthesis of purines, thymidylates, and certain
amino acids, which are essential for DNA synthesis and cell
multiplication.
53
Inthisexample,weusedtheexperimentaldrugMetoprine(CID:
24466) as a query. According to DrugBank (PAN: DB04655), its
annotated target is Histamine N-methyltransferase (HNMT).
54
For its 13 neighbor compounds identiﬁed by BASS (Figure 2B),
none was found targeting HNMT according to the available
target annotations. On the other hand, further investigation
indicated that three neighbor compounds, Pyrimethamine
(CID: 4993), NSC302325 (CID: 327404), and Methylbenzo-
prim (CID: 72438
55,56) had been previously reported targeting
DHFR. According to DrugBank (PAN: DB00205), Pyrimetha-
minewasan FDA-approvedantimalarial drugthrough amodeof
action by inhibiting DHFR.
53 Based on ChEMBL annotation
(PubChem BioAssay identiﬁer, AID: 55830), NSC302325 was a
DHFR inhibitor with an IC50 of 0.85 μM.
57 The direct annota-
tion of DHFR as a target of Methylbenzoprim was not available
in any of the above four databases. However, its annotated target
in ChEMBL (AID: 56179 and 56314), bifunctional dihydrofo-
late reductase-thymidylate synthase (DHFR-TS), was found to
be closely related with DHFR (BLAST E-value = 6e-136). The
bindingofMethylbenzoprimtoDHFRwasfurthersupportedby
previous NMR experiments
55 as well as molecular modeling
studies.
56 Using either one of the three compounds Pyrimetha-
mine,NSC302325andMethylbenzoprimasaquery,BASScould
identify Metoprine as a neighbor compound (Simbio = 0.800,
0.845,and0.829;p-value=9.4e-4,3.7e-4,and4.8e-4,respectively).
Moreover, all three compounds were structurally related to the
queryMetoprine(Simchem=0.950,0.707,and0.848,respectively).
Therefore, it is natural to consider DHFR as a potential target of
Metoprine, which was conﬁrmed by further investigation into
the target annotation in TTD (DrugID: DCL000304) and
precedent literatures.
58 60
Predicting Polypharmacology. Polypharmacology is receiv-
ing increasing attention indrug discovery for exploring both side
effects and new therapeutic opportunities.
61 As a step forward,
BASScanbereadilyappliedforpredictingthepolypharmacology
of a given compound by collecting known targets from its
Figure 2. Chemical similarity as a function of biological similarity for the neighbor compounds of (A) Paclitaxel and (B) Metoprine retrieved by
bioactivity proﬁle similarity search, respectively. The red-labeled neighbor compounds were those veriﬁed to share the common target with Paclitaxel
(microtubule) and Metoprine (dihydrofolate reductase), respectively.2444 dx.doi.org/10.1021/ci200192v |J. Chem. Inf. Model. 2011, 51, 2440–2448
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neighborcompounds.Here,wepresentedsuchanexampleusing
theapproveddrugAmsacrine(CID:2179)asaquery(Figure3).
A total of 67 neighbor compounds were identified by BASS.
More than a dozen of them were known DNA intercalators or
cross-linkers according to DrugBank annotations and/or pre-
cedent literatures. There were also several neighbor compounds
that were previously reported as inhibitors of topoisomerase,
type II alpha (TOP2A). The two targets of DNA and TOP2A
werealsoannotatedforAmsacrineinDrugBank(PAN:DB00276).
Additionally, Amsacrine together with one neighbor compound
(CID: 2708; PAN: DB00291) were confirmed to interact with
the enzyme glutathione S-transferase A2 (GSTA2). In a quanti-
tative high-throughput screening assay (AID: 886) launched by
theUSNationalInstitutesofHealthChemicalGenomicsCenter
(NCGC), both Amsacrine and its neighbor compound (CID:
3246719) demonstrated inhibitory activity against hydroxyacl-
coenzyme A dehydrogenase, type II (HADH2). In another
bioassay (AID: 410) conducted by NCGC, Amsacrine and two
neighbor compounds (CID: 24360 and 148869) were both
found active against cytochrome P450, family 1, subfamily A,
polypeptide 2 (CYP1A2). Therefore, it is straightforward to
depict a polypharmacological graph of Amsacrine by gathering
available target information predicted from its neighbor com-
pounds (Figure 3).
’DISCUSSION
The promising results from the overall evaluation of the
predicted compound-target associations and those shown in
the above examples demonstrated that bioactivity proﬁle simi-
larity search (BASS) may be applied to predict new targets for
drugs and bioactive compounds from the target annotations of
their neighbor compounds that are available in public databases.
Nevertheless, for a larger number of target predictions, we were
not able to verify them due to insuﬃcient target annotations in
public databases or due to diﬃculty in literature searching. It thus
remainsinterestingforfurther(experimental) studiestoverifythe
targets predicted here, especially for those resulting from signiﬁ-
cant bioactivity proﬁle similarity. For those completely unchar-
acterizedbioactivecompounds,BASSmayalsobehelpfultotarget
identiﬁcationbysuggestingpotentialtargetsaggregatedfromtheir
biologicalneighborcompounds.Tofacilitatethereadersofinterest,
we included a list of query compounds which yet have no target
annotation in any of the above four public databases or precedent
literatures and their neighbor compounds with known target
annotations (Supporting Information, Table S4).
Itshouldbementionedthatthecompound-targetassociations
identiﬁed in this work were veriﬁed retrospectively by taking
advantage of the target annotations derived from public data-
bases or by literature searching, and we emphasize that this work
could not have been done without the open access to public
databases which now contain vast amount of chemical biology
data. For a number of cases (e.g., microtubule example), the
predictions were strongly convincing as supported by the crystal
structures of ligand-target complexes. Nevertheless, for other
cases, the reported compound-target annotations in relevant
databases or literatures may require further investigation to
better understand the underlying mechanism of binding. For
example, though Paclitaxel and Vinblastine both bind to micro-
tubule, they actually bind at very diﬀerent sites, which may be
responsible for their diﬀerent modes of action. To address these
issues, structural biology studies, such as NMR or X-ray diﬀrac-
tion experiments, would be particularly persuasive. With the
growing availability of public databases containing ligand-target
annotations, such asDrugBank, TTD, ChEMBL, andPubChem,
the accuracy of BASS may be further improved.
Figure 3. Polypharmacology of Amsacrine. Compounds (labeled with PubChem compound identiﬁer, CID) and targets are denoted as ellipses and
rectangles,respectively.Theedgelinkingbetweenindicatesthatthereisacompound-targetassociation.ThequerycompoundAmsacrine(CID:2179)is
coloredwithcyan.DNA:DNA;TOP2A:topoisomerase,typeIIalpha;HADH2:hydroxyacyl-coenzymeAdehydrogenase,typeII;GSTA2:glutathione
S-transferase A2; CYP1A2: cytochrome P450, family 1, subfamily A, polypeptide 2.2445 dx.doi.org/10.1021/ci200192v |J. Chem. Inf. Model. 2011, 51, 2440–2448
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Lead optimization based on chemical scaﬀoldhas been broadly
embraced by medicinal chemists
62 as a central guiding principle
to design ligands with higher potency and/or more desirable
physicochemical properties.
63 It will be interesting to look
into the chemical space of the neighbor compounds identiﬁed
by BASS (Figure 4 and Supporting Information, Figure S2).
Figure 4A shows the number of neighbor compounds within
certain range of chemical similarity as a function of bioactivity
proﬁle similarity using all query-neighbor pairs in the bioactivity
proﬁle database. As one can see, BASS was able to identify not
only structurally similar neighbor compounds but also a con-
siderable number of structurally dissimilar ones with related
bioactivities. These may provide novel molecules or new starting
points for future ligand design, which would not have been
discovered by conventional medicinal chemistry eﬀorts. There-
fore, BASS has the appealing capability of ‘scaﬀold hopping’,a s
demonstrated in the above microtubule example and the data
shown in Figure 4B as a whole. It thus represents a new strategy
for identifying candidate compounds with diverse chemical
scaﬀolds that are biologically relevant to the aimed target. It is
worth stressing that the threshold of bioactivity proﬁle similarity
for deﬁning a neighbor compound is user adjustable, though
a conservative threshold of 0.75 was used in this work. In fact,
when a less stringent threshold of 0.70 (p-value = 5.22e-3) or
lower was applied in BASS, we could still verify a number of
predictions.
The idea ofusingbioactivity proﬁle(patternor ﬁngerprint)is,
of course, not entirely new. Other similar ideas have been
proposed. Nevertheless, computational approaches making use
of diﬀerent proﬁling data may vary, in particular, toward achiev-
ingdiﬀerentresearchgoals.Forexample,the“ConnectivityMap”
approachdevelopedbyLamb etal.
12employs mRNAexpression
proﬁles to establish connections between small molecules and
with diseases. The “biospectra analysis” approach by Fliri
et al.
64,65 aims to group compounds with related inhibitory
bioactivities against a panel of protein targets and correlate to
biological functions. Our speciﬁc goal in this work is to associate
compounds with targets based on the similar NCI-60 cell lines
Figure 4. The number of neighbor compounds within certain range of chemical similarity as a function of bioactivity proﬁle similarity for the query-
neighbor pairs of (A) the 2335 query compounds and their neighbor compounds (44,368 in total) and (B) the 284 veriﬁed target predictions,
respectively. The ﬁve columns (from left to right) in each bin of bioactivity proﬁle similarity correspond to the chemical similarity range of [0.0 0.2),
[0.2 0.4), [0.4 0.6), [0.6 0.8), and [0.8 1.0], respectively.2446 dx.doi.org/10.1021/ci200192v |J. Chem. Inf. Model. 2011, 51, 2440–2448
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bioactivityproﬁlesofsmall-moleculecompoundsandtheirtarget
annotationsinpublicdatabases.Weanticipatethat BASSmaybe
of beneﬁt to the target identiﬁcation for anticancer drug dis-
covery.AnalysisusingBASScouldgeneratehypothesis tounder-
stand both the mode of action and mechanism of binding for
bioactive compounds by suggesting new targets from well-
characterized neighbor compounds. Our work could contribute
to the target prediction and the state-of-art drug repositioning.
The free-of-charge screening service provided by the DTP/NCI
would make BASS more appealing. By submitting their own
compoundsofinterest,researcherscouldobtainhigh-qualityand
conﬁdential bioactivity proﬁles, which in turn can be used as
inputs for BASS to identify potential targets by consulting the
known targets of compounds in the bioactivity proﬁle database.
Nevertheless, before additional experiments are done, it should
be mentioned that BASS may only be applicable for identifying
the targets of the compounds which can cause cellular responses
in the NCI-60 cell lines.
’CONCLUSIONS
We have presented a computational approach, BASS, for
mutually identifying compound-target associations by compar-
ing the bioactivity proﬁles that are derived from the NCI-60 cell
lines.Whentwocompoundssharesimilarbioactivityproﬁles,the
targets of either compound may be considered as the potential
targets for the other compound. To evaluate BASS, each
compound in the bioactivity proﬁle database was used as a query
to search against the entire database for neighbor compounds
that may share common targets. An overall success rate of 44.8%
was achieved for the predicted compound-target associations by
using the prior knowledge of target annotations from public
databases, and it was further improved to nearly 50% when
consideringrelatedproteintargets.AnalysisshowsthatBASSnot
only could identify structurally similar bioactive compounds that
are biological relevant to the target of interest but also had the
powerofsuggestingnovelchemicalscaﬀoldsfortheaimedtarget.
Moreover, BASS may represent an eﬃcient strategy for integrat-
ing experimental data and target information newly emerged for
any of the neighbor compounds. Therefore, BASS may be
applied to suggest new targets for old drugs and provide insight
into anticancer drug discovery, facilitating the study of the
toxicity, promiscuity, and polypharmacology of drugs and bioac-
tive compounds.
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